<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31719072</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.</ArticleTitle><Pagination><StartPage>e029449</StartPage><MedlinePgn>e029449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e029449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2019-029449</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure and with an average life expectancy of 3-5 years post diagnosis. The use of complementary medicine such as medicinal cannabis in search for a potential treatment or cure is common in ALS. Preclinical studies have demonstrated the efficacy of cannabinoids in extending the survival and slowing of disease progression in animal models with ALS. There are anecdotal reports of cannabis slowing disease progression in persons with ALS (pALS) and that cannabis alleviated the symptoms of spasticity and pain. However, a clinical trial in pALS with these objectives has not been conducted.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">The Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease trial is a randomised, double-blind, placebo-controlled cannabis trial in pALS conducted at the Gold Coast University Hospital, Australia. The investigational product will be a cannabis-based medicine extract (CBME) supplied by CannTrust Inc., Canada, with a high-cannabidiol-low-tetrahydrocannabinol concentration. A total of 30 pALS with probable or definite ALS diagnosis based on the El Escorial criteria, with a symptom duration of &lt;2 years, age between 25 and 75years and with at least 70% forced vital capacity (FVC) will be treated for 6 months. The primary objective of the study is to evaluate the efficacy of CBME compared with placebo in slowing the disease progression measured by differences in mean ALS Functional Rating Scale-Revised and FVC score between the groups at the end of treatment. The secondary objectives are to evaluate the safety and tolerability of CBME by summarising adverse events, the effects of CBME on spasticity, pain, weight loss and quality of life assessed by the differences in mean Numeric Rating Scale for spasticity and Numeric Rating Scale for pain, percentage of total weight loss and ALS specific quality of life-Revised questionnaire.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The study has been approved by the local Institutional Review Board. The results of this study will be published in a peer-reviewed journal.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT03690791.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Urbi</LastName><ForeName>Berzenn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurology, Gold Coast Hospital and Health Service, Southport, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Griffith University, Gold Coast, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broadley</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology, Gold Coast Hospital and Health Service, Southport, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Griffith University, Gold Coast, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Duke University, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Ethan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>International Cannabis and Cannabinoids Institute, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabet</LastName><ForeName>Arman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology, Gold Coast Hospital and Health Service, Southport, Queensland, Australia Arman.Sabet@health.qld.gov.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Griffith University, Gold Coast, Queensland, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03690791</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064086">Medical Marijuana</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064086" MajorTopicYN="N">Medical Marijuana</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cannabinoid</Keyword><Keyword MajorTopicYN="N">cannabis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword></KeywordList><CoiStatement>Competing interests: The investigational product has been provided by CannTrust Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31719072</ArticleId><ArticleId IdType="pmc">PMC6858175</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2019-029449</ArticleId><ArticleId IdType="pii">bmjopen-2019-029449</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;55. 10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S, Carr K, Reiley L, et al. . A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int 2015;6:171 10.4103/2152-7806.169561</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 2009;10:310&#x2013;23. 10.3109/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, et al. . Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 2015;7:181&#x2013;93. 10.2147/CLEP.S37505</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A, Sclerosis AL. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;72. 10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Bowser R, Bruijn L, et al. . Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:19&#x2013;32. 10.3109/21678421.2013.778554</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.778554</ArticleId><ArticleId IdType="pmc">PMC4284067</ArticleId><ArticleId IdType="pubmed">23678877</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter GT, Rosen BS. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2001;18:264&#x2013;70. 10.1177/104990910101800411</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/104990910101800411</ArticleId><ArticleId IdType="pubmed">11467101</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004;141:775&#x2013;85. 10.1038/sj.bjp.0705667</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705667</ArticleId><ArticleId IdType="pmc">PMC1574256</ArticleId><ArticleId IdType="pubmed">14757702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair J. An introduction to cannabis and the endocannabinoid system. Australian Journal of Herbal Medicine 2016;28:107&#x2013;25.</Citation></Reference><Reference><Citation>De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009;23:1&#x2013;15. 10.1016/j.beem.2008.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2008.10.013</ArticleId><ArticleId IdType="pubmed">19285257</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 2010;160:480&#x2013;98. 10.1111/j.1476-5381.2010.00735.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2010.00735.x</ArticleId><ArticleId IdType="pmc">PMC2931550</ArticleId><ArticleId IdType="pubmed">20590559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Dick JRT, Pryce G, et al. . Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006;20:1003&#x2013;5. 10.1096/fj.05-4743fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4743fje</ArticleId><ArticleId IdType="pubmed">16571781</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting A, Weydt P, Hong S, et al. . Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 2004;89:1555&#x2013;7. 10.1111/j.1471-4159.2004.02544.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02544.x</ArticleId><ArticleId IdType="pubmed">15189359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Moore DH, Makriyannis A, et al. . AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006;542:100&#x2013;5. 10.1016/j.ejphar.2006.05.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2006.05.025</ArticleId><ArticleId IdType="pubmed">16781706</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman C, McAllister SD, Rizvi G, et al. . Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33&#x2013;9. 10.1080/14660820310016813</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310016813</ArticleId><ArticleId IdType="pubmed">15204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker JL, Seely KA, Reed RL, et al. . The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101:87&#x2013;98. 10.1111/j.1471-4159.2006.04346.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04346.x</ArticleId><ArticleId IdType="pmc">PMC2819701</ArticleId><ArticleId IdType="pubmed">17241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Hong S, Witting A, et al. . Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:182&#x2013;4. 10.1080/14660820510030149</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510030149</ArticleId><ArticleId IdType="pubmed">16183560</ArticleId></ArticleIdList></Reference><Reference><Citation>Laaris N, Good CH, Lupica CR. &#x394;9-Tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 2010;59:121&#x2013;7. 10.1016/j.neuropharm.2010.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.04.013</ArticleId><ArticleId IdType="pmc">PMC2882293</ArticleId><ArticleId IdType="pubmed">20417220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez BG, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904&#x2013;13. 10.1523/JNEUROSCI.4540-04.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4540-04.2005</ArticleId><ArticleId IdType="pmc">PMC6726060</ArticleId><ArticleId IdType="pubmed">15728830</ArticleId></ArticleIdList></Reference><Reference><Citation>ALSUntangled Group ALSUntangled No. 16: cannabis. Amyotroph Lateral Scler 2012;13:400&#x2013;4. 10.3109/17482968.2012.687264</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.687264</ArticleId><ArticleId IdType="pubmed">22632446</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo-Porras F, Piscitelli F, Verde R, et al. . Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. J Neuroimmune Pharmacol 2015;10:233&#x2013;44. 10.1007/s11481-015-9602-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-015-9602-4</ArticleId><ArticleId IdType="pubmed">25819934</ArticleId></ArticleIdList></Reference><Reference><Citation>Amtmann D, Weydt P, Johnson KL, et al. . Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95&#x2013;104. 10.1177/104990910402100206</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/104990910402100206</ArticleId><ArticleId IdType="pubmed">15055508</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelinas D, Miller RG, Abood ME. A pilot study of safety and tolerability of delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3.</Citation></Reference><Reference><Citation>Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 2010;81:1135&#x2013;40. 10.1136/jnnp.2009.200642</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.200642</ArticleId><ArticleId IdType="pubmed">20498181</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Sorar&#xf9; G, et al. . Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (canals): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2019;18:155&#x2013;64. 10.1016/S1474-4422(18)30406-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30406-X</ArticleId><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter GT, Abood ME, Aggarwal SK, et al. . Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 2010;27:347&#x2013;56. 10.1177/1049909110369531</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049909110369531</ArticleId><ArticleId IdType="pubmed">20439484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction 2011;106:2195&#x2013;203. 10.1111/j.1360-0443.2011.03574.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1360-0443.2011.03574.x</ArticleId><ArticleId IdType="pubmed">21749524</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez R, Schuster RM, Mermelstein RJ, et al. . Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol 2012;34:962&#x2013;76. 10.1080/13803395.2012.703642</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13803395.2012.703642</ArticleId><ArticleId IdType="pmc">PMC3488122</ArticleId><ArticleId IdType="pubmed">22882144</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbi B, Owusu MA, Hughes I, et al. . Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta&#x2010;analysis. J Neurochem 2019;149:284&#x2013;97. 10.1111/jnc.14639</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14639</ArticleId><ArticleId IdType="pubmed">30520038</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martet M, Espejo-Porras F, Fern&#xe1;ndez-Ruiz J, et al. . Changes in Endocannabinoid Receptors and Enzymes in the Spinal Cord of SOD1 G93ATransgenic Mice and Evaluation of a Sativex -like Combination of Phytocannabinoids: Interest for Future Therapies in Amyotrophic Lateral Sclerosis. CNS Neurosci Ther 2014;20:809&#x2013;15. 10.1111/cns.12262</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12262</ArticleId><ArticleId IdType="pmc">PMC6493201</ArticleId><ArticleId IdType="pubmed">24703394</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163:1344&#x2013;64. 10.1111/j.1476-5381.2011.01238.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01238.x</ArticleId><ArticleId IdType="pmc">PMC3165946</ArticleId><ArticleId IdType="pubmed">21749363</ArticleId></ArticleIdList></Reference><Reference><Citation>Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012;2:241&#x2013;54. 10.1177/2045125312457586</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045125312457586</ArticleId><ArticleId IdType="pmc">PMC3736954</ArticleId><ArticleId IdType="pubmed">23983983</ArticleId></ArticleIdList></Reference><Reference><Citation>Devinsky O, Cilio MR, Cross H, et al. . Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55:791&#x2013;802. 10.1111/epi.12631</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12631</ArticleId><ArticleId IdType="pmc">PMC4707667</ArticleId><ArticleId IdType="pubmed">24854329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals 2012;5:529&#x2013;52. 10.3390/ph5050529</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph5050529</ArticleId><ArticleId IdType="pmc">PMC3763649</ArticleId><ArticleId IdType="pubmed">24281562</ArticleId></ArticleIdList></Reference><Reference><Citation>
Queensland Health 
Clinical guidance: for the use of medicinal cannabis products in Queensland, 2017.  Available: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf
</Citation></Reference><Reference><Citation>Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol 2016;7 10.3389/fphar.2016.00309</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00309</ArticleId><ArticleId IdType="pmc">PMC5022003</ArticleId><ArticleId IdType="pubmed">27683558</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 2018;49:12&#x2013;19. 10.1016/j.ejim.2018.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2018.01.004</ArticleId><ArticleId IdType="pubmed">29307505</ArticleId></ArticleIdList></Reference><Reference><Citation>Stott CG, White L, Wright S, et al. . A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69:1135&#x2013;47. 10.1007/s00228-012-1441-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-012-1441-0</ArticleId><ArticleId IdType="pubmed">23179176</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>